IRYS (IRYS) fluctuates 41.3% in 24 hours: Trading volume surge drives speculative price volatility
Bitget Pulse2026/04/20 05:05Volatility Overview
In the past 24 hours, the price of IRYS rebounded from a low of $0.02531 to a high of $0.03575, currently quoted at $0.03552, with a volatility amplitude of 41.3%. Trading volume has increased significantly, with multi-platform data showing that 24-hour spot trading volume surged 225% to about $29.5 million, futures trading volume reached $29.2 million, and total turnover was approximately $22.76 million to $31.8 million, up 168.9% from the previous day.
Summary of the Cause of Abnormal Fluctuations
- Abnormal trading volume surge: 24-hour trading volume jumped from the usual level to the $20-30 million range; spot buy orders expanded 8.2 times, sell orders 3.2 times, resulting in a quick price spike followed by a pullback.
- Active leveraged futures: Leveraged trading on platforms such as Binance futures drove volatility higher, accompanied by net capital inflow and buy pressure signals, but no obvious sign of stop-loss hunting.
There were no official announcements, large whale on-chain transfers, or major news events within 24 hours—speculative trading was the main driver.
Market Views and Outlook
Community sentiment is mostly dominated by traders, optimistic about the price reaching $0.044 after breaking through the $0.0275-$0.0342 support zone, but there are warnings about retracement risks if support fails or forced liquidation occurs. Mainstream opinions highlight that high leverage speculation can easily trigger extreme volatility; short-term market is likely to fluctuate, and attention should be paid to trading volume sustainability.
Note: This analysis was automatically generated by AI based on public data and on-chain monitoring and is for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Marvell Technology (MRVL.US) plummets after earnings: Beating forecasts is not enough—Wall Street thinks Google (GOOGL.US) orders are recognized too slowly
Although Marvell Technology's latest financial report and future revenue guidance both superficially exceeded market expectations, its stock price still plummeted in pre-market trading on Friday.

Gold prices could soar to $12,000 if US national debt keeps rising, says strategist
PURR stock hits record $14.15 as Hyperliquid revenue tops $718 million
From Lowering Blood Sugar and Weight Loss to Cardiovascular Protection! Mounjaro Achieves "Cardiometabolic Leap," Lilly (LLY.US) Opens GLP-1's Second Growth Curve
Eli Lilly's diabetes drug Mounjaro has received approval in the United States for reducing the risk of serious cardiovascular disease. The U.S. Food and Drug Administration has approved Mounjaro for lowering cardiovascular risk in adults with type 2 diabetes who have established heart disease.
